Healthcare Resource Utilization and Costs Following the Initiation of Various Lines of Therapy Among Patients With Relapsed/Refractory Multiple Myeloma
Estrin A, Chansakul A, Conroy B, Hughes D, Nador G, Meche A, Chaudhary MA, Mathew S, Dibonaventura M
EHA 2025
- 欧洲血液年会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Treatment Patterns and Effectiveness in an Anti-CD38 and Lenalidomide Pretreated RRMM Population: Data From Two Real-World Datasets
Mohan M, Kortum M, Baljevic M, Farrell J, Zhuleku E, McDonald K, Meche A, Demers A-S, Ashman O, Hughes D, Nador G, Ruckert M, Theurich S
EHA 2025
- 欧洲血液年会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
Differences Across Countries in Healthcare Provider Confidence With CAR-T and Bispecific Antibody Therapies for Relapsed/Refractory Multiple Myeloma
Zamagni E, Brigle K, Cormier N, San Miguel M, Biru Y, Davies R, Greenwood A, Watkins J, Farrell J, Ailawadhi S
EHA 2025
- 欧洲血液年会 2025
| 肿瘤 | 血液肿瘤 | 易瑞欧
